JP2009518415A5 - - Google Patents

Download PDF

Info

Publication number
JP2009518415A5
JP2009518415A5 JP2008544453A JP2008544453A JP2009518415A5 JP 2009518415 A5 JP2009518415 A5 JP 2009518415A5 JP 2008544453 A JP2008544453 A JP 2008544453A JP 2008544453 A JP2008544453 A JP 2008544453A JP 2009518415 A5 JP2009518415 A5 JP 2009518415A5
Authority
JP
Japan
Prior art keywords
composition
solvate
composition according
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008544453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518415A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/046449 external-priority patent/WO2007067570A1/en
Publication of JP2009518415A publication Critical patent/JP2009518415A/ja
Publication of JP2009518415A5 publication Critical patent/JP2009518415A5/ja
Withdrawn legal-status Critical Current

Links

JP2008544453A 2005-12-05 2006-12-05 疾患の処置のための方法および組成物 Withdrawn JP2009518415A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74257805P 2005-12-05 2005-12-05
US76497906P 2006-02-03 2006-02-03
US81784706P 2006-06-30 2006-06-30
PCT/US2006/046449 WO2007067570A1 (en) 2005-12-05 2006-12-05 Methods and compositions for the treatment of disease

Publications (2)

Publication Number Publication Date
JP2009518415A JP2009518415A (ja) 2009-05-07
JP2009518415A5 true JP2009518415A5 (enExample) 2011-01-27

Family

ID=37877059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008544453A Withdrawn JP2009518415A (ja) 2005-12-05 2006-12-05 疾患の処置のための方法および組成物

Country Status (6)

Country Link
US (1) US20090018136A1 (enExample)
EP (1) EP1965803A1 (enExample)
JP (1) JP2009518415A (enExample)
AU (1) AU2006321942A1 (enExample)
CA (1) CA2631740A1 (enExample)
WO (1) WO2007067570A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055511A2 (en) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
KR101002490B1 (ko) * 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
ES2524026T3 (es) 2008-01-03 2014-12-03 Biomarin Pharmaceutical Inc. Análogo de pterina para tratar una afección que responde a BH4
WO2009138437A1 (en) * 2008-05-13 2009-11-19 Genmedica Therapeutics Sl Salicylate conjugates useful for treating metabolic disorders
US20100239552A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination Therapies for Treating Metabolic Disorders
US8575217B2 (en) * 2009-03-16 2013-11-05 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
CA3130908A1 (en) 2009-06-30 2010-12-30 Mallinckrodt Hospital Products IP Limited Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
WO2011019399A1 (en) * 2009-08-13 2011-02-17 Medstar Health Research Institute, Inc. Preservation of blood vessels using phosphodiesterase inhibitors
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
MX2015000810A (es) * 2012-07-19 2015-06-05 Relypsa Inc Composiciones que comprenden polímeros reticulados con enlace a cationes.
US20150013695A1 (en) * 2013-07-10 2015-01-15 Ahkeo Ventures LLC Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
CN104530054B (zh) * 2014-12-19 2018-01-19 扬子江药业集团有限公司 盐酸优克那非的多晶型物及其制备方法
JP7553906B2 (ja) * 2018-11-01 2024-09-19 宏 一瀬 Ｓｐｒをコードするポリヌクレオチドを含む組換えベクター、及びそれを含む組成物
WO2021009091A1 (en) * 2019-07-15 2021-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and treating cardiac dysfunction
WO2022173818A1 (en) * 2021-02-09 2022-08-18 University Of Virginia Patent Foundation Use of biliverdin reductase b inhibitors to allow malaria eradication in patients with g6pd deficiency

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2601215A (en) * 1948-03-17 1952-06-17 American Cyanamid Co Process of preparing dihydropterins
US3505329A (en) * 1968-02-06 1970-04-07 Smithkline Corp Process for the synthesis of biopterin
JPS5883691A (ja) * 1981-11-13 1983-05-19 Kanegafuchi Chem Ind Co Ltd １′，２′−ジアシル−（６ｒ，ｓ）−５，６，７，８−テトラヒドロ−ｌ−ビオプテリンおよびその製法
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
ZA836957B (en) * 1982-09-20 1985-04-24 Wellcome Found Neurologically active chemical compounds
GB8318833D0 (en) * 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
US5196533A (en) * 1983-04-11 1993-03-23 South Alabama Medical Science Foundation, Usa Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines
US4587340A (en) * 1983-09-19 1986-05-06 Burroughs Wellcome Co. Biopterin analogs
JPS60178887A (ja) * 1984-02-23 1985-09-12 Kanegafuchi Chem Ind Co Ltd ５，６，７，８−テトラヒドロ−ｌ−ビオプテリンの製造法
JPS60199889A (ja) * 1984-03-24 1985-10-09 Kanegafuchi Chem Ind Co Ltd ５，６，７，８−テトラヒドロ−ｌ−エリスロ−ビオプテリンの硫酸塩およびその製法
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
DE3437944A1 (de) * 1984-10-17 1986-07-31 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verwendung von pterinen zur steigerung der aktivitaet von lymphokinen und anderen blutfaktoren, sowie ein diagnostisches oder therapeutisches praeparat, das pterine in kombination mit lymphokinen enthaelt
CA1262347A (en) * 1985-01-28 1989-10-17 Suntory Limited Preparation process of (6r)-tetrahydro-l-biopterin
JPS61277618A (ja) * 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
EP0318926B1 (en) * 1987-11-30 1995-05-03 Kabushiki Kaisha Vitamin Kenkyusyo Intermediates for synthesizing 5,6,7,8-tetrahydro-L-erythro-biopterin and its derivatives
JP2534423B2 (ja) * 1991-12-26 1996-09-18 コーネル・リサーチ・ファンデーション・インコーポレイテッド 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤
US5198547A (en) * 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
DE4308739C1 (de) * 1993-03-19 1994-06-23 Henning Berlin Gmbh Pterinderivate, ihre Herstellung und ihre Verwendung
US5945452A (en) * 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5502050A (en) * 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
US5753656A (en) * 1994-08-05 1998-05-19 Suntory Limited Method for treating spinocerebellar degeneration
US20020076782A1 (en) * 1996-07-05 2002-06-20 John P.N. Rosazza Purified nitric oxide synthase
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
JP4306825B2 (ja) * 1998-02-27 2009-08-05 アスビオファーマ株式会社 インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤
US6200758B1 (en) * 1999-02-19 2001-03-13 New York State Office Of Mental Health Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
WO2000056328A1 (en) * 1999-03-19 2000-09-28 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE0000307D0 (sv) * 2000-01-31 2000-01-31 Univ Zuerich Method and formulation för treatment of vasoconstriction
US6544994B2 (en) * 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
US20050119270A1 (en) * 2000-08-04 2005-06-02 Mason R. P. Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
US20030007961A1 (en) * 2001-06-22 2003-01-09 Wilburn Michael D. Orthomolecular vitamin E derivatives
US20030078231A1 (en) * 2001-06-22 2003-04-24 Wilburn Michael D. Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
US6685458B2 (en) * 2001-10-11 2004-02-03 Acushnet Company Split metal die assembly with injection cycle monitor
WO2005018620A2 (en) * 2003-08-26 2005-03-03 Cell Center Cologne Gmbh Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
US7067659B2 (en) * 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
JP2008523090A (ja) * 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド 新生児肺高血圧症の治療のための方法および組成物
TW200719896A (en) * 2005-04-18 2007-06-01 Astrazeneca Ab Combination product
WO2006120176A2 (en) * 2005-05-11 2006-11-16 Nycomed Gmbh Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative

Similar Documents

Publication Publication Date Title
JP2009518415A5 (enExample)
US10413532B2 (en) Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
JP2010536849A5 (enExample)
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
EP2444072A3 (en) Non-mucoadhesive film dosage forms
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
CN1440283A (zh) 有机化合物的联合形式
HK1208803A1 (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
EP2283826A3 (en) Galenic formulations of organic compounds
JP2008515905A5 (enExample)
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
JP2016539156A5 (enExample)
HRP20131233T1 (hr) Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
CA2668320A1 (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
JP2010518168A5 (enExample)
WO2006116148A3 (en) (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
JP2005517040A5 (enExample)
EA201401042A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
JP2009517411A5 (enExample)
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2007111983A3 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
JP2011516544A5 (enExample)
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи